Related Experiment Video
Updated: Nov 21, 2025

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Re-reading ACT, BCG, and Low COVID-19 in Africa
Jia Bainga Kangbai1,2,3, Lawrence Sao Babawo3,4, Daniel Kaitibi5
1Center for International Health, University of Munich (LMU), Munich, Germany.
Insights
Countries with low malaria and tuberculosis (TB) incidence show higher COVID-19 cases and deaths. Researchers suggest artemisinin-based combination therapy (ACT) and bacillus Calmette-Guérin (BCG) vaccine may offer protection.
Area of Science:
- Epidemiology
- Infectious Diseases
- Global Health
Background:
- The COVID-19 pandemic has shown a geographically disproportionate distribution of cases and deaths.
- Countries with low burdens of malaria and tuberculosis (TB) appear to have higher COVID-19 incidence and mortality.
Purpose of the Study:
- To investigate the correlation between low malaria/TB prevalence and high COVID-19 outcomes.
- To propose a potential therapeutic strategy for COVID-19 containment and management.
Main Methods:
- Observational analysis of global COVID-19 data in relation to 2018 malaria and TB case numbers.
- Speculative analysis based on the potential immunomodulatory effects of artemisinin-based combination therapy (ACT) and bacillus Calmette-Guérin (BCG) vaccine.
Main Results:
- A significant association was observed between low malaria/TB endemicity and elevated COVID-19 cases and fatalities.
- Hypothesized that prior exposure to malaria and subsequent use of ACT drugs, along with BCG vaccination for TB, might confer some protection against severe COVID-19.
Conclusions:
- The study calls for a COVID-19 containment and clinical management protocol incorporating ACT drugs and BCG vaccine on a compassionate use basis.
- Further research is warranted to explore the potential protective effects of these interventions against COVID-19.
Abstract:
October 11, 2020, marks the seventh month since the World Health Organization (WHO) officially declared COVID-19 a pandemic. Unlike other coronavirus diseases, there is a geographically disproportionate distribution of the incidence of COVID-19 cases around the world. We observed a significantly high COVID-19 cases and deaths in countries and territories with no or very small number of malaria cases or no or low national TB cases in 2018. We speculate that the high incidence of COVID-19 cases and deaths in countries less affected by malaria is partly due to overexposure to malaria which led to the regular use of the artemisinin anti-malaria drugs as well as the regular use of bacillus Calmette-Guérin (BCG) vaccine for TB prevention. The vaccine produced an almost life-long immunity to TB and meningitis to its recipients. We are thus calling for a COVID-19 containment and clinical management protocol that will incorporate the use of the anti-malaria ACT drug cocktail and BCG vaccine on compassionate ground.
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Bias in Epidemiological Studies
Causality in Epidemiology
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pareto Chart
The Pareto chart is named after the Italian economist Vilfredo Pareto, who described the Pareto...

